Elucidating the effect of a new indoline derivative (AN1284) against Non-alcoholic steatohepatitis

The aim of the current study was to check whether chronic treatment with AN1284 could reverse steatosis and fibrosis in a mouse model of NASH. We used a mouse model of dietary induced NASH that was given for 4 month. Treatment with saline or AN1284 was given via implanted minipumps for 2 month. Treatment was started after 2 month feeding. Our results revealed that AN1284 significantly attenuated liver damage, as indicated by a reduced liver/body ratio, decreased ALT serum levels, a significant reduction in liver fat content and hepatic fibrosis. To investigate the underlying mechanism, we performed RNA sequencing on mice fed with normal diet (ND) or high fat diet (HFD; Envigo-Teklad TD.150235). Overall design: Mice were fed with normal diet (ND) or high fat diet (HFD; Envigo-Teklad TD.150235), and given either saline or AN1284 in two doses, 1mg and 5mg per kg per day. At least 3 replicates were performed for each condition.